tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Bristol-Myers Squibb: Solid Near-Term Execution and 2026 EPS Boost from Eliquis, but Limited Long-Term Visibility Supports Hold Rating
PremiumRatingsBristol-Myers Squibb: Solid Near-Term Execution and 2026 EPS Boost from Eliquis, but Limited Long-Term Visibility Supports Hold Rating
7d ago
Bristol Myers price target raised to $40 from $37 at Morgan Stanley
Premium
The Fly
Bristol Myers price target raised to $40 from $37 at Morgan Stanley
11d ago
Trump Trade: Argentina says U.S. to cut hundreds of tariffs
Premium
The Fly
Trump Trade: Argentina says U.S. to cut hundreds of tariffs
11d ago
Reiterating Buy on Bristol-Myers Squibb: Near-Term Outperformance and Pipeline-Driven Upside Support Higher $68 Target
PremiumRatingsReiterating Buy on Bristol-Myers Squibb: Near-Term Outperformance and Pipeline-Driven Upside Support Higher $68 Target
11d ago
Bristol-Myers Squibb Bets On New Growth Engines
Premium
Company Announcements
Bristol-Myers Squibb Bets On New Growth Engines
12d ago
Reiterating Buy on Bristol-Myers Squibb: Milvexian’s Validated FXIa Mechanism and Underappreciated Stroke Prevention Upside Support $65 Target
Premium
Ratings
Reiterating Buy on Bristol-Myers Squibb: Milvexian’s Validated FXIa Mechanism and Underappreciated Stroke Prevention Upside Support $65 Target
12d ago
Bristol Myers sees 2026 WW revenue growth of Eliquis 10%-15%
PremiumThe FlyBristol Myers sees 2026 WW revenue growth of Eliquis 10%-15%
12d ago
Bristol Myers reports Q4 adjusted EPS $1.26, consensus $1.20
Premium
The Fly
Bristol Myers reports Q4 adjusted EPS $1.26, consensus $1.20
12d ago
Bristol Myers sees FY26 adjusted EPS $6.05-$6.35, consensus $6.04
Premium
The Fly
Bristol Myers sees FY26 adjusted EPS $6.05-$6.35, consensus $6.04
12d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100